WuXi Biologics (2269.HK) — market event timeline
NashNova tracks 4 market events mentioning WuXi Biologics (2269.HK) between 2026-06-05 and 2026-06-22, each with a dated one-line analysis of how the event relates to the asset.
- Survey: China's Biotech Closing In on the U.S., Already Leading in Clinical Development and Supply Chain
A leading Chinese CRO/CDMO and a core beneficiary of China's leadership in clinical development and supply chain capabilities; also a direct target of the proposed BIOSECURE Act restrictions.
- Novo Nordisk Plans $69M Investment Over 6 Years to Build Obesity Drug Incubator in Europe
The European incubator could spawn more biotech startups, and WuXi Biologics, as a leading CDMO, stands to capture their outsourced manufacturing demand.
- Jefferies: Multinational Pharma Companies Can Hardly Give Up China's Cost Efficiency
Sister company of WuXi AppTec, also a leading Chinese CXO player, previously named in the BIOSECURE Act, with highly correlated policy risks.
- Eli Lilly and Novo Nordisk Shift Obesity Drug Expansion Focus Beyond the U.S. Market
Global demand for GLP-1 biosimilars and CDMO services is rising as overseas markets expand. WuXi Biologics is a major biologics contract manufacturer.
For research and information only — not investment advice.